Access Vascular
Bedford, US · Founded 2015 · Delaware corporation · 3 known investors
Find your way into Access Vascular
290 people in our graph share verified history with the Access Vascular team — schools, employers, funds. One of them is your warm intro.
Joe SantaBarbaraunlockedknows Katie Motherway · together at Stonehill College (overlapped)
×7knows the team · via Bentley University
knows the team · via NinePoint Medical
knows the team · via Stonehill College
knows the team · via T2 Biosystems
knows the team · via Saint John's High School
Access Vascular develops thrombus-evading intravascular catheters made from a proprietary biomaterial, offering an FDA-cleared PICC and the HydroMID peripherally inserted midline catheter to reduce vascular access complications. The company designs and manufactures its medical devices for clinical use in the United States.
Founders & leadership
Access Vascular was founded in 2015 by James Biggins.
JB
James BigginsinFounder · President and CEO
DB
Dennis ByrneinChief Commercial OfficerDennis Byrne brings over 20 years of medical device commercialization experience, spanning early-stage companies and established organizations, with expertise in product launches, team building, and revenue scaling. As Chief Commercial Officer of Access Vascular, he leads commercial strategy for the company's thrombus-evading intravascular catheter portfolio.
SB
Scott BloodinVP of Regulatory and QualityScott Blood is VP of Regulatory and Quality at Access Vascular, where he leads compliance systems and quality operations for the company's intravascular catheter devices. He has held leadership roles in medical device quality and regulatory affairs, with expertise in device quality systems, regulatory compliance, risk management, and design validation.
KM
Katie MotherwayinVP of Human ResourcesKatie Motherway is VP of Human Resources at Access Vascular, where she has led operational and organizational functions including HR, accounting, and finance since the company's early stages through its transition to a scaled commercial manufacturing organization.
PS
Paul SabinNamed on SEC filing
JP
Joseph PellegrinoNamed on SEC filing
BR
Brent RatzNamed on SEC filing
AD
Aaron DynesController
Investors · 3
Reported raises · per SEC filings
Form D private placements$51.8M disclosed across 5 of 6 rounds · 2017–2023
▶$20.6MraisedOct 2023 · 19 investors · BiotechnologyRule 506(b)
▶$20.6MraisedOct 2023 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JJ PelligrinoDirector
- Amine BentalebDirector
- James BigginsExecutive Officer
- Luc MarengereDirector
- Michael R JaffDirector
- Marc RiviereDirector
- Brent SabinDirector
- Offering amount
- $31.6M
- Amount sold
- $20.6M
- Minimum investment
- $8K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MofferedOct 2022 · 2 investors · BiotechnologyRule 506(b)
▶$10MofferedOct 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Luc MarengereDirector
- Brent SabinDirector
- James BigginsExecutive Officer
- JJ PelligrinoDirector
- Michael R JaffDirector
- Marc RiviereDirector
- Amine BentalebDirector
- Offering amount
- $10M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.9MraisedMar 2021 · 14 investors · BiotechnologyRule 506(b)
▶$19.9MraisedMar 2021 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JJ PelligrinoDirector
- Paul SabinDirector
- Brent RatzDirector
- James BigginsExecutive Officer
- Michael R JaffDirector
- Amine BentalebDirector
- Luc MarengereDirector
- Alexandra MacLeanDirector
- Offering amount
- $19.9M
- Amount sold
- $19.9M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MraisedSep 2019 · 15 investors · BiotechnologyRule 506(b)
▶$5.6MraisedSep 2019 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul SabinDirector
- James BigginsExecutive Officer
- JJ PelligrinoDirector
- Brent RatzDirector
- Offering amount
- $7.3M
- Amount sold
- $5.6M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.9MraisedMay 2018 · 7 investors · BiotechnologyRule 506(b)
▶$1.9MraisedMay 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brent RatzDirector
- Paul SabinDirector
- Joseph PellegrinoDirector
- James BigginsExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $1.9M
- Minimum investment
- $25K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3.8MraisedAug 2017 · 25 investors · BiotechnologyRule 506(b)
▶$3.8MraisedAug 2017 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul SabinDirector
- Joseph PellegrinoDirector
- James BigginsExecutive Officer, Director
- Brent RatzDirector
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- Minimum investment
- $15K
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapivWatch149 shared keywordsivWatch develops sensors and monitoring systems that detect peripheral IV infiltrations and extravasations at early stages to prevent patient harm in hospital settings. The company serves healthcare providers and hospitals globally through direct partnerships and a network of distributors.
Medbridge148 shared keywordsMedbridge is a digital health platform that serves healthcare providers with evidence-based clinical content and tools designed to improve patient outcomes in rehabilitation, physical therapy, and related care settings. The company supports over 360,000 healthcare providers across 4,000+ organizations with educational resources, care management platforms, and AI-assisted care solutions.
Companies competing with Access Vascular for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Access Vascular do?
- Access Vascular develops thrombus-evading intravascular catheters made from a proprietary biomaterial, offering an FDA-cleared PICC and the HydroMID peripherally inserted midline catheter to reduce vascular access complications. The company designs and manufactures its medical devices for clinical use in the United States.
- Who founded Access Vascular?
- Access Vascular was founded by James Biggins in 2015.
- Who are Access Vascular's investors?
- Access Vascular's investors include TVM Capital Life Science, Green Park & Golf Ventures, TVM Capital.
- How much funding has Access Vascular raised?
- Access Vascular has disclosed $51.8M raised across 5 of its 6 known rounds.
- Where is Access Vascular headquartered?
- Access Vascular is headquartered in Bedford, US.